At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
STTK Shattuck Labs, Inc.
Not Yet Opened 10-21 16:00:00 EDT
5.58
-0.26
-4.45%
盘后5.58
+0.000.00%
19:30 EDT
High6.00Low5.57Vol1.20M
Open5.85D1 Closing5.84Amplitude7.36%
Mkt Cap560.03MTradable Cap378.10MTotal Shares100.36M
T/O6.82MT/O Rate1.77%Tradable Shares67.76M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Shattuck Labs to Present SL-846 Bispecific Antibody Data at UEG Week 2026
Reuters  ·  10-13
Shattuck Labs to Present SL-846 Bispecific Antibody Data at UEG Week 2026
Shattuck Labs Announces Two Poster Presentations at UEG Week 2026
GlobeNewswire  ·  10-13
Shattuck Labs Announces Two Poster Presentations at UEG Week 2026
Shattuck Labs Price Target Announced at $17.00/Share by UBS
Dow Jones  ·  10-12
Shattuck Labs Price Target Announced at $17.00/Share by UBS
UBS Initiates a Buy Rating on Shattuck Labs (STTK)
TIPRANKS  ·  10-12
UBS Initiates a Buy Rating on Shattuck Labs (STTK)
Analysts Offer Insights on Healthcare Companies: Encompass Health (EHC), Shattuck Labs (STTK) and Arcus Biosciences (RCUS)
TIPRANKS  ·  10-05
Analysts Offer Insights on Healthcare Companies: Encompass Health (EHC), Shattuck Labs (STTK) and Arcus Biosciences (RCUS)
Shattuck Labs Price Target Raised to $14.00/Share from $11.00 by Wedbush
Dow Jones  ·  10-02
Shattuck Labs Price Target Raised to $14.00/Share from $11.00 by Wedbush
Piper Sandler Remains a Buy on Shattuck Labs (STTK)
TIPRANKS  ·  10-02
Piper Sandler Remains a Buy on Shattuck Labs (STTK)
Shattuck Labs price target raised to $19 from $17 at Needham
TIPRANKS  ·  10-02
Shattuck Labs price target raised to $19 from $17 at Needham
Shattuck Labs Inc : Needham Raises Target Price to $19 from $17
THOMSON REUTERS  ·  10-02
Shattuck Labs Inc : Needham Raises Target Price to $19 from $17
Analysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK) and Atricure (ATRC)
TIPRANKS  ·  10-02
Analysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK) and Atricure (ATRC)
Wedbush Lifts Price Target on Shattuck Labs to $14 From $11, Keeps Outperform Rating
MT Newswires Live  ·  10-01
Wedbush Lifts Price Target on Shattuck Labs to $14 From $11, Keeps Outperform Rating
Shattuck Labs (STTK) Receives a Buy from Leerink Partners
TIPRANKS  ·  10-01
Shattuck Labs (STTK) Receives a Buy from Leerink Partners
Shattuck Labs Plans Phase 2 Trial of Chronic Inflammatory Skin Disease Drug
MT Newswires Live  ·  10-01
Shattuck Labs Plans Phase 2 Trial of Chronic Inflammatory Skin Disease Drug
Shattuck Labs Names Shoba Ravichandran Senior Vice President, Clinical Development
Reuters  ·  10-01
Shattuck Labs Names Shoba Ravichandran Senior Vice President, Clinical Development
Shattuck Labs - Phase 2 Trial to Start in 2026; 16-Week Data Expected in H1 2028
THOMSON REUTERS  ·  10-01
Shattuck Labs - Phase 2 Trial to Start in 2026; 16-Week Data Expected in H1 2028
Shattuck Labs - Existing Cash Expected to Fund Operations into 2029
THOMSON REUTERS  ·  10-01
Shattuck Labs - Existing Cash Expected to Fund Operations into 2029
Shattuck Labs - to Initiate Phase 2 Trial of Sl-325 in Hidradenitis Suppurativa
THOMSON REUTERS  ·  10-01
Shattuck Labs - to Initiate Phase 2 Trial of Sl-325 in Hidradenitis Suppurativa
Shattuck Labs - Ind Submission for Phase 2 Trial Expected in October 2026
THOMSON REUTERS  ·  10-01
Shattuck Labs - Ind Submission for Phase 2 Trial Expected in October 2026
Shattuck Labs Announces Phase 2 Clinical Trial of Sl-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.d., as Senior Vice President, Clinical Development
THOMSON REUTERS  ·  10-01
Shattuck Labs Announces Phase 2 Clinical Trial of Sl-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.d., as Senior Vice President, Clinical Development
Pantginis Maintains Buy on Shattuck as Merck TL1A/DR3 Data De-Risk SL-325; Price Target Reiterated at $14
TIPRANKS  ·  10-01
Pantginis Maintains Buy on Shattuck as Merck TL1A/DR3 Data De-Risk SL-325; Price Target Reiterated at $14

Introduction

Company Name.
Shattuck Labs, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Issue price:
--